Table 2.
Modelled cost-benefit findings for TAVI compared with SAVR in the Netherlands
| Summary results | TAVI | SAVR | Incremental |
|---|---|---|---|
| Cost per patient | €44,149 | €39,407 | €4742 |
| Life year gained (undiscounted) | 12.67 | 11.89 | 0.79 |
| Median survival (years) | 15.00 | 13.17 | 1.83 |
| QALYs per patient | 9.50 | 8.62 | 0.89 |
| Incremental cost-effectiveness ratio (ICER) | €5346 | ||
| Incremental net monetary benefit (NMB) | €39,615 | ||
| Incremental net health benefit (NHB) | 0.79 | ||
| Acute phase cost (initial procedure) | |||
| Index hospitalization (without pacemaker)– including rehabilitation | €36,190 | €29,140 | €7050 |
| Acute phase costs | €36,190 | €29,140 | €7050 |
| Additional costs at 1 year | |||
| MI | €123 | €84 | €38 |
| Costs of pacemaker complications | €25 | €15 | €10 |
| Costs of rehospitalizations | €177 | €265 | –€88 |
| Re-intervention costs | €163 | €161 | €1 |
| Alive and well health state costs | €270 | €181 | €89 |
| Treated AF health state costs | €45 | €350 | –€305 |
| DS costs | €46 | €181 | –€135 |
| Death costs | €0 | €0 | €0 |
| Total costs at 1 year | €36,190 | €29,140 | €7,050 |
| Additional lifetime costs | |||
| Costs of pacemaker complications | €241 | €140 | €101 |
| Costs of rehospitalizations | €266 | €252 | €15 |
| Re-intervention costs | €4,171 | €3,642 | €529 |
| Alive and well health state costs | €750 | €474 | €276 |
| Treated AF health state costs | €722 | €3075 | –€2353 |
| DS costs | €1808 | €2684 | –€876 |
| Death costs | €0 | €0 | €0 |
| Additional lifetime costs | €7959 | €10,267 | –€2308 |
| Total lifetime costs | €44,149 | €39,407 | €4742 |
AF, atrial fibrillation; DS, disabling stroke; ICER, incremental cost-effectiveness ratio; MI, myocardial infarction; NHB, Net health benefit; NMB, net monetary benefit; QALY, quality of life adjusted year; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation